Asgard Therapeutics raises EUR 6M in Seed Financing to exploit direct in vivo reprogramming
Asgard Therapeutics AB, a private biotech company which originate from Lund University’s Cell Reprogramming and Immunity lab, led by the WCMM Fellow Professor Filipe Pereira, has announced the completion of a EUR 6 million seed financing round. The financing was co-led by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden. Filipe Pereira is Asgard’s Co-Founder and Head of Innovati
https://www.wcmm.lu.se/article/asgard-therapeutics-raises-eur-6m-seed-financing-exploit-direct-vivo-reprogramming - 2025-10-03